Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$183.58M+747.02%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Frank Leonard
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 1,605
- Beta
- 0.99
- Country
- CH
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.84
Financials
Revenue
$183.58M+747.0%Net Income
$-15.66MEBITDA
$-6.25MFree Cash Flow
$5.53MEPS (diluted)
$-0.13Shares Outstanding (diluted)
116.01M+35.3%Operating Expenses
$153.04MCash & Debt
$440.56MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $655.35M | $-136.23M | $-1.22 |
| 2024 | $605.22M | $-168.63M | $-1.56 |
| 2023 | $509.34M | $-207.04M | $-1.95 |
| 2022 | $537.84M | $-92.53M | $-0.88 |
| 2021 | $535.03M | $-58.35M | $-0.56 |
| 2020 | $494.37M | $19.81M | $0.20 |
| 2019 | $351.32M | $-7.23M | $-0.07 |
| 2018 | $248.07M | $-63.56M | $-0.69 |
| 2017 | $177.03M | $-61.66M | $-0.70 |
| 2016 | $82.89M | $-131.84M | $-1.54 |
| 2015 | $33.09M | $-111.58M | $-1.34 |
| 2014 | $15.49M | $-80.68M | $-1.12 |
| 2013 | $10.36M | $-77.37M | $-6.43 |
Valuation
NVCRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
130+30.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·9d ago·Positive
Novocure: A Mispriced Cash-Generating Biotech With Upside Potential NovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption accelerating, especially for new launches like Optune Pax. Valuation multiples are below sector medians (EV/Sales 2.05x vs. 3.66x), while the pipeline and upcoming Optune Mya launch offer significant upside.
View source ↗ - Newsmarketbeat.com·34d ago·Neutral
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference.
View source ↗ - Newsseekingalpha.com·38d ago·Positive
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·45d ago·Neutral
Novocure Reports Patient Data Exposure in Cybersecurity Incident NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
View source ↗ - Newszacks.com·55d ago·Neutral
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗
Earnings
Thu, Oct 29(in 6 days)
Consensus estimate $-0.23 per share
Typical surprise +21.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$-0.13 vs $-0.33beat
- Thu, Apr 30$-0.62 vs $-0.51miss
- Thu, Feb 26$-0.22 vs $-0.41beat
- Thu, Oct 30$-0.33 vs $-0.42beat
- Thu, Jul 24$-0.36 vs $-0.39beat
- Thu, Apr 24$-0.31 vs $-0.47beat
Estimates and results for NVCR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NVCR officers and directors.
- Bought
- $1.2m
- Sold
- $3.3m
4 trades
25 trades
- Leonard Frank Xsold
- Leung Gabrielsold
- Stafford Kristinsold
- Ocean Allyson Jsold
- Scannell Timothy Jsold
- Hilleman Jeryl Lsold
- Vernon W Anthonysold
- Hung Davidsold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (22d later)Buy$1,001 - $15,000
- Marie Newmanhouse · IL03 · disclosed Aug 5, 2021 (34d later)Buy$15,001 - $50,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (313d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.